Maxim Group Cuts Autonomix Medical (NASDAQ:AMIX) Price Target to $2.00

Autonomix Medical (NASDAQ:AMIX) had its target price lowered by Maxim Group from $5.00 to $2.00 in a report published on Tuesday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $2.00.

Autonomix Medical Price Performance

NASDAQ:AMIX opened at $0.38 on Tuesday. The firm has a market capitalization of $2.59 million, a price-to-earnings ratio of -0.11 and a beta of -2.58. The business has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.86. Autonomix Medical has a 1 year low of $0.34 and a 1 year high of $3.09.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10. As a group, analysts expect that Autonomix Medical will post -10 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.